- Home
- MBBC vs COEP Comparison
MBBC vs COEP Comparison
Compare MBBC & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- COEP
- Stock Information
- Founded
- MBBC 1902
- COEP 2017
- Country
- MBBC United States
- COEP United States
- Employees
- MBBC N/A
- COEP N/A
- Industry
- MBBC Banks
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBBC Finance
- COEP Health Care
- Exchange
- MBBC Nasdaq
- COEP Nasdaq
- Market Cap
- MBBC 29.3M
- COEP 27.4M
- IPO Year
- MBBC N/A
- COEP N/A
- Fundamental
- Price
- MBBC $10.08
- COEP $10.92
- Analyst Decision
- MBBC
- COEP
- Analyst Count
- MBBC 0
- COEP 0
- Target Price
- MBBC N/A
- COEP N/A
- AVG Volume (30 Days)
- MBBC 4.3K
- COEP 55.9K
- Earning Date
- MBBC 08-22-2025
- COEP 08-15-2025
- Dividend Yield
- MBBC N/A
- COEP N/A
- EPS Growth
- MBBC 103.56
- COEP N/A
- EPS
- MBBC 0.22
- COEP N/A
- Revenue
- MBBC $6,591,743.00
- COEP $62,874.00
- Revenue This Year
- MBBC N/A
- COEP N/A
- Revenue Next Year
- MBBC N/A
- COEP N/A
- P/E Ratio
- MBBC $45.77
- COEP N/A
- Revenue Growth
- MBBC N/A
- COEP N/A
- 52 Week Low
- MBBC $6.38
- COEP $2.31
- 52 Week High
- MBBC $12.00
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- COEP 57.24
- Support Level
- MBBC N/A
- COEP $11.30
- Resistance Level
- MBBC N/A
- COEP $12.71
- Average True Range (ATR)
- MBBC 0.00
- COEP 0.91
- MACD
- MBBC 0.00
- COEP 0.09
- Stochastic Oscillator
- MBBC 0.00
- COEP 47.27
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.